HC Wainwright Says Talaris' Technology Unprecedented In Cell Therapy Space
HC Wainwright initiated coverage on Talaris Therapeutics Inc (NASDAQ: TALS) with a Buy rating and a price target of $18.
Talaris leverages its novel “facilitated” allogeneic hematopoietic stem cell (Allo-HSCT) transplantation platform for solid organ transplantation, autoimmune diseases, and severe blood, immune and metabolic disorders.
The facilitated Allo-HSCT attempts to unify two immune systems into one (chimerism) such that both the donor and recipient immune cells function harmoniously in the recipient.
Earlier today, Talaris received a report of a patient death, which triggered a pre-specified, temporary stopping requirement and review by the FREEDOM-1 Data Monitoring Committee (DMC).
The analyst views the attributes of Talaris’ technology as unprecedented in the cell therapy space and holding potential for broad market adoption in kidney transplants and other indications.
If approved by the end of 2026, HC Wainwright expects FCR001 could achieve over $1 billion in sales in the U.S. by 2030, with significant room for upside growth in the succeeding years.
The analyst also notes investor concerns regarding treatment-related GvHD incidence and writes that physicians perceive mild Grade 2 GvHD as a recurring event in kidney transplant patients.
Price Action: TALS shares are down 44.63% at $1.34 on the last check Thursday.
Latest Ratings for TALS
Date | Firm | Action | From | To |
|---|---|---|---|---|
Nov 2021 | SVB Leerink | Maintains | Outperform | |
Jun 2021 | Morgan Stanley | Initiates Coverage On | Overweight | |
Jun 2021 | Guggenheim | Initiates Coverage On | Buy |
View More Analyst Ratings for TALS
View the Latest Analyst Ratings
See more from Benzinga
Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
